Retatrutide — commonly referred to as reta in patient communities — has generated more anticipation in obesity medicine than perhaps any drug in the last decade. As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it works through mechanisms that go beyond appetite suppression alone, addressing food noise, metabolic rate, and energy expenditure in ways that single- or dual-receptor drugs cannot fully replicate. With Phase 3 data now showing a mean weight loss of 28.7% at 68 weeks in the TRIUMPH-4 trial — the highest figure ever recorded in a Phase 3 obesity trial — the question on every patient's mind is simple: when will retatrutide be FDA approved?
The honest clinical answer is: not yet, but the trajectory is serious. Here is a clear-eyed breakdown of where things stand as of 2026.
No. As of April 2026, retatrutide has not received FDA approval and has not been approved by any regulatory agency anywhere in the world. The drug remains an investigational compound — meaning it is only available through clinical trials and has not been cleared for commercial prescription use in any country. Patients encountering retatrutide outside of a formal clinical trial setting should be aware that no regulatory body has validated its safety or efficacy for general use.
That said, the clinical data supporting retatrutide is among the strongest ever assembled for an anti-obesity medication, and the path toward regulatory submission is taking shape.
The most significant recent development is the Phase 3 TRIUMPH-4 trial data, announced by Eli Lilly in December 2025. Participants treated with retatrutide 12mg for 68 weeks achieved a mean body weight reduction of 28.7%. To put that in perspective, semaglutide 2.4mg (Wegovy) produced approximately 14.9% mean weight loss over 68 weeks in its pivotal STEP-1 trial, and tirzepatide 15mg (Zepbound) produced approximately 20.9% mean weight loss over 72 weeks in SURMOUNT-1. Retatrutide at its highest studied dose more than doubles the semaglutide benchmark.
As of April 2026, a New Drug Application (NDA) for retatrutide has not yet been filed with the FDA by Eli Lilly. The anticipated NDA filing was projected for late 2025 based on the TRIUMPH trial completion schedule, but peer-reviewed Phase 3 publication is still pending as of April 2026. NDA submission typically follows the completion and analysis of all Phase 3 data, along with preparation of the full regulatory package — a process that takes months after trial readout.
As of the time of this writing, Eli Lilly has not publicly confirmed an NDA filing for retatrutide. The standard FDA review period following NDA acceptance is 10 to 12 months. If the FDA grants Priority Review — a designation reserved for drugs offering significant improvement over available therapies — that timeline could be shortened to approximately 6 months. Whether retatrutide will receive Priority Review or Breakthrough Therapy Designation should be confirmed through official Eli Lilly filings and FDA communications; those designations have not been publicly confirmed in available sources at the time of publication.
What is clear is that the TRIUMPH trial enrollment closure signals Phase 3 data collection is nearing or at completion, which is a prerequisite for NDA submission. Observers of the regulatory process will be watching for an official filing announcement closely.
As of mid-2025, retatrutide is not approved in any country — not in the United States, the European Union, the United Kingdom, Canada, Japan, or elsewhere. It remains an investigational new drug. Patients should be cautious about any claims suggesting otherwise.
The data make a compelling case that retatrutide will eventually reach patients through formal approval — but several factors could affect the timeline:
| Drug | Mechanism | Trial Duration | Mean Weight Loss | FDA Approved |
|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | GLP-1 agonist | 68 weeks | ~14.9% | Yes (2021) |
| Tirzepatide 15mg (Zepbound) | GLP-1 / GIP dual agonist | 72 weeks | ~20.9% | Yes (2023) |
| Retatrutide 12mg (investigational) | GLP-1 / GIP / Glucagon triple agonist | 68 weeks | 28.7% | No |
The progression across generations of these drugs is striking. Each receptor added to the agonist profile appears to contribute meaningfully to outcomes, and retatrutide's glucagon receptor activity is thought to play a particular role in increasing energy expenditure — effectively turning up the body's metabolic rate rather than relying on appetite reduction alone to drive results.
Before TRIUMPH-4, the Phase 2 obesity trial published in the New England Journal of Medicine in 2023 provided the first large-scale human efficacy data. At 48 weeks, participants on 8mg retatrutide achieved up to 22.8% mean weight loss, with 100% of participants in that arm achieving at least 5% weight reduction and up to 70% achieving 20% or greater weight loss. The 12mg arm reached 24.2% mean weight loss at 48 weeks, with 48% of participants losing 25% or more of their body weight. These were remarkable figures — and TRIUMPH-4 has now surpassed them in a larger, longer Phase 3 setting.
Cardiometabolic markers also improved significantly in Phase 2. Fasting triglycerides fell by 34% in the 12mg group at 24 weeks, total cholesterol dropped by 17.3%, and LDL cholesterol decreased by approximately 15.6 to 16.9% in the 8mg arms. Quality of life scores on the SF-36v2 improved across all active dose groups.
Retatrutide represents a potential turning point in how obesity is treated — not as a lifestyle failure, but as a complex metabolic disease that responds to precision pharmacotherapy. For patients who have followed the GLP-1 and GLP-1/GIP story closely and want to stay ahead of what comes next, staying informed is the most important step available right now. The waitlist at glp3md.com is designed to keep interested patients updated on the retatrutide FDA approval timeline, TRIUMPH Phase 3 data releases, and regulatory milestones as they unfold. Joining the waitlist does not guarantee access to medication, treatment, or a prescription — retatrutide is not FDA-approved, and no promises about future availability can or should be made. What the waitlist does offer is a reliable, clinically grounded source of information so that when the landscape does change, patients are ready.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.